Third-party tested Independent lab verified Batch COA Lot-matched documentation Tracked shipping Dispatched with tracking Secure checkout Encrypted payment Questions before ordering
For weight management, NICE has approved: Semaglutide 2.4 mg (TA875) for adults with a BMI of 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity, and for some people with BMI 30-34.9 kg/m meeting specific criteria
MOTS-c targets AMPK-dependent insulin sensitization Regulatory status / FDA lists both peptides among bulk drug substances under evaluation for compounding Why No Direct Comparison Exists Neither AOD-9604 nor MOTS-c has advanced far enough in clinical development for a randomized head-to-head trial
This information helps inform decisions about continued use and identifies any concerning trends early
(First Alert 4) - With GLP-1 weight-loss drugs becoming more common, doctors are working to better understand how they affect the bodyand what patients can expect beyond weight loss